Rating Change
Goldman Sachs analysts upgraded Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) from Sell to Neutral on October 08, 2026.
upgradeNASDAQ:RCKT
Rocket Pharmaceuticals, Inc. (RCKT) Upgraded to Neutral at Goldman Sachs
Goldman Sachs analysts upgraded Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) from Sell to Neutral on October 08, 2026.
At publication ·
What changed
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) · upgrade
- Firm
- Goldman Sachs
- Rating
- Sell to Neutral
- Price at event
- $2.63
- Market capitalization
- $372.8M
At a glance
Key takeaways
- Goldman Sachs upgraded Rocket Pharmaceuticals from Sell to Neutral on October 8, 2026, suggesting analysts see improving fundamentals or better risk-reward dynamics.
Market Context
Rocket Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $2.63 with a market capitalization of $372.8M.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Goldman Sachs's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rocket Pharmaceuticals, Inc.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | Goldman Sachs | Neutral | N/A |
| Oct 07, 2026 | Leerink Partners | Market Perform | N/A |
| Oct 07, 2026 | Wedbush | Outperform | N/A |
| Oct 07, 2026 | Chardan Capital | Buy | N/A |
| Sep 16, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RCKT Stock Page
Frequently Asked Questions
What does the Neutral rating mean for RCKT?
A rating of Neutral from Goldman Sachs reflects the analyst's outlook on Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RCKT forecast page.